News & Media
SK life science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK life science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
3/10/2020
SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)
Full release12/06/2019
SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting
Full release12/02/2019
SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741
Full release11/21/2019
FDA Approves XCOPRI® (cenobamate tablets) CV, an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.
Full release11/13/2019
Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology
Full release11/01/2019
New National Epilepsy Survey Reveals Significant Disconnects on Important Issues Among Patients, Caregivers and Healthcare Professionals
Full release7/17/2019
SK life science Expands Support for the J. Kiffin Penry Epilepsy Education Programs to Reach More Healthcare Providers
Full release5/13/2019
SK life science Provides Update on Recent Company Milestones and Accomplishments
Full release5/03/2019
SK life science to Showcase Scientific Data at the 2019 American Academy of Neurology Annual Meeting
Full release2/15/2019
SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe
Full release